China's National Development and Reform Commission (NDRC), one of China’s three agencies responsible for antitrust enforcement, recently published its decisions to fine three Chinese companies active in the manufacture of estazolam (a drug commonly used to treat insomnia) for refusing to supply estazolam active pharmaceutical ingredients (APIs) to other estazolam tablet manufacturers and raising estazolam tablet prices. The conduct was held to have infringed China’s Anti-Monopoly Law (AML) which prohibits, among other things, price-fixing and joint-boycotts. The NDRC imposed total fines of approximately RMB 2.6 million (approximately USD 418,057) on the three companies. The decisions are the latest in a series of antitrust enforcement actions following drug price reforms in China in
Share on
|
|
The Chinese NDRC fines three manufacturers of an insomnia drug for refusing to supply its pharmaceutical ingredients to other competitors and for raising its prices (Huazhong / Xinyi / Siyao)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
